Regenxbio (RGNX) Misses Q4 EPS by 28c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights
February 26, 2020 4:05 PM ESTROCKVILLE, Md., Feb. 26, 2020 /PRNewswire/ --
Additional data from RGX-314 Phase I/IIa trial for wet AMD expected in 1H 2020 RGX-314 clinical trials for treatment of wet AMD and diabetic retinopathy expected to advance in 2020 using subretinal and suprachoroidal delivery approaches Additional interim data from RGX-121 Phase I/II trial for MPS II expected in 2020 Plans to expand rare disease pipeline into neuromuscular disorders in 2H 2020 $400 million in cash, cash equivalents and marketable securities as of December 31, 2019 Conference call Wednesday, February 26th at... More